Although PCI initially carries higher costs than medical therapy alone for patients with abnormal fractional flow reserve, the difference narrows considerably when first-year follow-up costs are considered, according to FAME 2 data. The study of more than 1,200 patients with stable coronary artery disease and angiographically significant stenoses found those treated with PCI were less likely to need repeat revascularization. Experts said assessing FFR allows clinicians to zero in on functionally significant lesions, and appropriate use criteria should be updated accordingly.

Full Story:

Related Summaries